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Abstract
Background—Fatalities from opioid overdose quadrupled during the last 15 years as illicit 
opioid use increased. This study assesses how stigma and drug use settings are associated with 
non-fatal overdose to identify targets for overdose risk reduction interventions and inform 
overdose education and naloxone distribution programs.
Methods—We surveyed 444 people who used drugs in Baltimore, Maryland, USA, from 2009–
2013 as part of a randomized clinical trial of a harm reduction intervention. Participants reported 
demographic characteristics, drug use, overdose history, use of a local syringe services program, 
involvement in the local drug economy, and whether they experienced discrimination from others 
(i.e. enacted stigma) or stigmatized themselves (i.e., internalized stigma) related to their drug use. 
We used multinomial logistic regression models to identify correlates of experiencing a non-fatal 
overdose within the past year or >1 year ago relative to participants who never experienced an 
overdose.
Results—Stigma was positively associated with experiencing a nonfatal overdose in the past year 
(adjusted Odds Ratio [aOR]: 1.7, 95% Confidence Interval [CI]: 1.1–2.7) and >1 year ago (aOR 
[95% CI]: 1.5 [1.1–2.0]) after adjustment for demographic and substance use characteristics. The 
association of stigma with overdose was stronger for enacted versus internalized stigma. The 
number of public settings (shooting gallery, crack house, abandoned building, public bathroom, 
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outside) where participants used drugs was also positively associated with experiencing an 
overdose.
Conclusions—Stigma related to drug use and using drugs in more settings may increase 
overdose risk. The effectiveness of overdose prevention and naloxone training may be improved 
by reducing discrimination against people who use drugs in community and medical settings and 
diversifying the settings in which overdose prevention trainings are delivered. These efforts may 
be enhanced by use of peer outreach approaches in which people who use drugs diffuse prevention 
messages through their social networks and within settings of drug consumption outside the 
medical setting.
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Overdose; Stigma; Drug Use Settings
INTRODUCTION
The quadrupling of opioid overdose mortality in the US, and in Baltimore, during the past 
two decades highlights a pressing need to prevent both fatal and non-fatal overdose 
(National Institute on Drug Abuse, 2018). The urgent need to prevent overdoses has become 
only more evident alongside the recent surge in fentanyl-related deaths (Seth, Scholl, Rudd, 
& Bacon, 2018). Fentanyl overdose deaths in Baltimore City, where the data for the present 
study were collected, increased 36.8% from 2016 to 2017 from 419 to 573 deaths 
(MDHMH, 2017, 2018). Overdose mortality may be reduced by diffusing overdose 
prevention and response skills and training people who use drugs (PWUD) and other 
community members likely to witness an overdose to administer naloxone, a lifesaving 
overdose reversal antidote.
Preventing overdose fatalities requires identifying individuals who are at risk for opioid 
overdose and reducing their risk through harm reduction and other types of interventions 
(Hawk, Vaca, & D’Onofrio, 2015; Lagisetty, Bohnert, & Fendrick, 2018). Throughout the 
US, including in Baltimore, local programs have implemented overdose response training 
and distributed naloxone through existing syringe exchange programs (Green, Heimer, & 
Grau, 2008; K. E. Tobin, Sherman, Beilenson, Welsh, & Latkin, 2009) with apparent success 
in increasing participants’ knowledge and skills to respond to an overdose event (Seal et al., 
2005; Tobin et al., 2009). However, many individuals at risk of overdose do not frequent 
syringe exchange services, highlighting the need to diversify the locations providing harm 
reduction services (Beletsky et al., 2014; Gindi, Rucker, Serio- Chapman, & Sherman, 2009; 
Treloar & Cao, 2005). The current study sought to explore correlates of self-reported, non-
fatal overdoses, including stigma and drug use settings, among PWUD in Baltimore City to 
inform future overdose prevention efforts.
The self-stigma and discrimination experienced by PWUD because of their drug use (i.e., 
stigma related to drug use) has not been adequately considered as a risk factor for opioid 
overdose despite increasing evidence linking stigma with health outcomes, injection-related 
risk behaviors, and utilization of harm reduction services (Cama, Brener, Wilson, & von 
Hippel, 2016; Couto E Cruz, Salom, Dietze, et al., 2018; Kulesza, Larimer, & Rao, 2013; 
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Latkin et al., 2010; Rivera, DeCuir, Crawford, Amesty, & Lewis, 2014; von Hippel, Brener, 
& Horwitz, 2018; Wilson, Brener, Mao, & Treloar, 2014). Internalized stigma (i.e. self-
stigma), the negative feelings PWUD have about themselves because of their drug use, has 
been previously linked to depression and decreased psychological well-being (Cama et al., 
2016; Kulesza et al., 2013; von Hippel et al., 2018), which are known to increase overdose 
risk (Tobin & Latkin, 2003). Rivera and colleagues (2014) also found that among people 
who inject drugs, higher internalized stigma was associated with decreased recent use of 
syringe exchange programs. Additionally, enacted stigma (i.e. experiences of discrimination 
or being stereotyped because of drug use) has similarly been associated with depression and 
poor mental and physical well-being (Couto E Cruz, Salom, Dietze, et al., 2018; Kulesza et 
al., 2013), as well as with injection behaviors that increase overdose risk, such as being 
injected by someone else (Wilson et al., 2014). To our knowledge, only one study has 
examined the association of discrimination with overdose and found that experiencing 
discrimination because of drug use on a weekly or more frequent basis was associated with 
60% higher odds of overdosing (Couto E Cruz, Salom, Dietze, et al., 2018).
In addition to individual-level factors, the micro-level risk environment, specifically the 
settings in which people use drugs, may influence the outcome of an overdose. Using drugs 
in public spaces, such as abandoned buildings or outside, has been associated with both 
calling for medical help and fatal overdose compared to use in private spaces (e.g., a 
participant’s home) (Bohnert, Tracy, & Galea, 2009; Tracy et al., 2005). In addition, setting 
may influence bloodborne virus risk through its influence on injection norms and practices 
(Rhodes et al., 2006). However, it is unknown whether using drugs in public versus private 
settings influences whether an overdose occurs. Setting-specific drug use norms may 
influence overdose risk. People who use drugs in settings other than their private residences 
may have less control over what transpires, may rush to use, and/or may fear police or others 
interrupting their drug use. Additionally, the number of settings where drugs are used may 
be indicative of drug use frequency and addiction severity.
Examining contextual and structural risk factors for experiencing an overdose, such as 
stigma and drug use settings, could inform overdose prevention programming. The primary 
aim of this analysis was to examine how stigma was associated with overdose history. We 
anticipated that higher levels of internalized and enacted stigma would be positively 
associated with experiencing a drug overdose. The secondary aim was to assess how drug 
use settings relate to overdose history. We hypothesized that using drugs in more settings, 
and especially in public settings, would be positively associated with experiencing a drug 
overdose. Finally, we examined how other factors, including drug use, syringe exchange use, 
selling drugs, and demographic factors related to overdose history.
METHODS
Workshop Study
Study participants were recruited in Baltimore, Maryland from July 2009 to July 2013 as 
part of the Workshop study, a randomized clinical trial addressing psychological distress and 
HIV risk behaviors among inner-city PWUD residing in impoverished neighborhoods (Tobin 
et al., 2017). Recruitment was conducted through street-based outreach, word-of-mouth, 
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flyers, advertisements in local newspapers, and referrals from community agencies. 
Inclusion criteria for enrollment were: (1) age 18–55; (2) willing to attend group sessions, 
which was the mode of the clinical trial intervention; and (3) HIV risk behavior, satisfying at 
least one of the following categories: (3a) injected drugs more than 3 times in the past week, 
or (3b) snorted or sniffed heroin or cocaine or smoked crack in the past 6 months AND had 
one of the following sexual risk behaviors in the past 6 months: two or more sex partners, 
sex with a partner who injected drugs, sex with a partner who smoked crack, or sex with a 
partner who was HIV-positive. All study protocols were reviewed by the Johns Hopkins 
Bloomberg School of Public Health Institutional Review Board, and all participants 
provided written informed consent prior to study enrollment. Data reported here were 
obtained from the study’s baseline survey, which was conducted from 2009 to 2012. All 
drug use questions were administered via audio computer assisted self-interviewing 
(ACASI). The remaining data were collected during face-to-face interviews. The present 
analysis includes 444 study participants with complete data on survey items related to drug 
overdose, stigma, opioid use, drug use settings, and other measures described below.
Survey Measures
Overdose history—To assess history of experiencing drug overdose, participants were 
introduced to the definition of an overdose as “a life-threatening condition that occurs after 
someone has taken drugs by injection or by any other route.” They were then asked: (1) 
“How many times in your life have you overdosed?” and (2) “When was your most recent 
overdose?” The latter item served as the main outcome variable for analysis. Reports of 
experiencing an overdose were categorized as “in the past year,” “over a year ago,” or 
“never.” Lifetime overdose frequency was explored in a sensitivity analysis.
Opioid use and addiction treatment history—Participants estimated the last time 
they used several substances through various modes of administration. This analysis 
summarized the following items: sniffing or snorting heroin, injecting heroin, injecting 
speedball (a combination of heroin and cocaine), and using prescription opioids “to get 
high” (i.e., to become intoxicated). Participants reported whether their use was “in the past 
year,” “more than a year ago,” or “never.” Heroin and/or speedball injection were 
summarized as a single measure for the same time period. To identify participants who 
received addiction treatment, we summarized whether participants stayed overnight in a 
residential drug treatment program, attended an outpatient program, took buprenorphine, or 
took methadone “in the past year,” “more than a year ago,” or “never.” We summarized 
receipt of any addiction treatment using the participant’s most recent timeframe for any of 
the four treatments. Variable values for “never” were coded as 0, for “more than a year ago” 
were coded as 1, and “in the past year” were coded as 2.
Drug use settings—Participants were asked whether they had used substances in a 
variety of settings over the past six months. Settings included a place they lived, a friend’s 
residence, a “shooting gallery” (i.e. a location where PWUD gather to inject drugs), a “crack 
house,” (i.e. a location where PWUD gather to use drugs), an abandoned building, a public 
bathroom, and “outside” (i.e. street, park, alley, etc.). For the present analyses, these items 
were assessed both individually and in a combined score ranging from 0 to 7 settings 
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(median: 3). We also created two sub-scores reflecting the number of public spaces used 
(i.e., shooting gallery, crack house, abandoned building, public bathroom, and/or outside; 
range: 0–5, median: 1) and private spaces used (i.e. a place they lived or a friend’s residence; 
range: 0–2, median: 2).
Stigma related to drug use—An overall stigma measure was assessed using a 17-item 
scale of 10 questions about enacted stigma and 7 questions about internalized stigma 
(Supplemental Table 1). Enacted stigma questions captured discriminatory experiences and 
times when PWUD were treated differently because of their drug use when interacting with 
others (e.g., “Other people are uncomfortable around me because I use drugs”). Internalized 
stigma (i.e., self-stigma) referred to feelings that the participant had towards themselves 
because of their drug use (e.g., “I feel set apart, isolated from the rest of the world because 
of my drugs use”). Responses were recorded on a five-point scale from “(1) strongly 
disagree” to “(5) strongly agree.” We formed three measures by summing all 17-items, the 
10 enacted stigma items, and the 7 internalized stigma items. The overall scale’s Cronbach’s 
alpha was .91. The Cronbach alpha for internalised and enacted stigma were 0.85 and 0.89, 
respectively. For the analysis, responses were converted to z-scores to facilitate ease of 
interpretation.
Syringe exchange use, syringe and equipment sharing, & drug economy 
involvement—Participants were asked how often they exchanged syringes through the 
Baltimore City Needle Exchange Program (BCNEP) in the past six months. Participants 
who injected heroin and/or speedball in the past six months reported the number of different 
people they shared syringes with, defined as “using a needle after someone else.” For 
analysis, receptive syringe sharing was categorized as binary variable comparing participants 
who shared with >0 people versus did not share with anyone. Participants who injected 
heroin and/or speedball in the past six months also reported how often they shared 
equipment, defined as using a cooker previously used by another person, cotton used by 
another person, or rinse water after someone else had used it. Participants were considered to 
have shared equipment if they endorsed sharing at least one of these items. Syringe and 
equipment sharing were explored in bivariate analysis but were not included in the 
regression models as these questions were only asked of people who injected drugs within 
the last 6 months. Involvement in the drug economy was assessed by asking participants 
whether they sold drugs in the past six months.
Demographics—The survey assessed several demographic and socio-economic factors 
including age, race, gender, education, employment status, and homelessness. Participant 
age was dichotomized based on a median split (median=45).
Statistical Analysis
We compared the distributions of covariates between those who experienced an overdose 
within the last year, >1 year ago, and who never experienced an overdose. We tested for 
statistical differences in bivariate associations using chi-squared tests. We then used 
multivariable multinomial logistic regression to summarize the associations of covariates 
with experiencing an overdose within the last year or >1 year ago relative to participants 
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who never experienced an overdose. We included all variables with a chi-squared p-value 
<0.20 in the multivariable model (stigma, number of drug use settings, heroin and/or 
speedball injection, prescription opioid misuse, heroin snorting, syringe exchange use, 
addiction treatment, and selling drugs) as well as several demographic variables (age, 
gender, race, education, and homelessness) regardless of their statistical significance in 
bivariate associations. For regression models, we treated opioid use and addiction treatment 
variables as continuous ordinal measures ranging from 0–2 as described above. We assessed 
the relationship of stigma with overdose by using the 17-item z-score and total number of 
drug use settings as covariates in the main analysis and examined the enacted and 
internalized stigma scores and public and private drug use settings in three separate models 
as subanalyses. As a sensitivity analysis, we examined the association of stigma and number 
of drug use settings with the number of lifetime overdoses using zero-inflated negative 
binomial regression to account for the distributional form of overdose frequency (i.e. 
overdispersion [mean: 0.8 overdoses, variance: 2.0] and the large number of participants 
who had never experienced an overdose [62.6%]).
RESULTS
Sample Characteristics
This was an impoverished urban sample of 444 PWUD; 94.6% were unemployed, and 
36.9% were homeless in the last 6 months. Most participants were African American 
(85.4%), while 12.6% identified as white and 2.0% were categorized as “other.” Over half 
(58.1%) of the sample was male, and the median age was 45 years. Less than half (48.0%) 
completed high school. Nearly all participants (93.5%) used opioids, with 83.8% ever 
snorting heroin, 56.5% ever injecting heroin or speedball, and 35.8% ever misusing 
prescription opioids. Among those who injected heroin and/or speedball in the past 6 
months, 53.1% shared syringes and 81.8% shared other injection equipment respectively. A 
minority (13.1%) reported selling drugs in the past month. All 125 participants (28.2%) who 
exchanged syringes did so infrequently (less than once per month in the past 6 months). 
Nearly all (84.7%) had received some type of addiction treatment in their lifetime; 
buprenorphine maintenance treatment was most common. A total of 34 participants (7.7%) 
reported experiencing an overdose in the past year, 132 (30.2%) overdosed >1 year ago, and 
278 (62.6%) reported no history of overdose. Of the 7 injection settings, the median number 
reported was 3 (mean: 3.2). Most used in private settings (79.3% used where they lived and 
76.4% used at a friend’s residence). The most commonly used public setting was outdoor 
(49.5% of participants). Approximately one-third (36.1%) used in an abandoned building 
and one-quarter used in a public bathroom (26.8%), shooting gallery (25.1%), or crack 
house (24.8%).
Bivariate Analysis
Participants who overdosed (within the past year and >1 year ago) had higher average stigma 
scores than those who never overdosed (p<0.001, Table 1). This trend of higher stigma 
among those who overdosed persisted when the total stigma score was divided into its 
component enacted and internalized stigma scores (analysis of variance results for enacted: 
p<0.001, internalized: p=0.02). Participants who overdosed more commonly used drugs in 
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public spaces (a shooting gallery, crack house, abandoned building, public bathroom, or 
outside) compared to participants who never overdosed. Use of a syringe exchange program, 
selling drugs, receiving addiction treatment (residential, methadone, or buprenorphine), 
injecting heroin or speedball, snorting heroin, and misuse of prescription opioids were 
positively associated with experiencing an overdose. A higher proportion of participants who 
never overdosed were African American relative to those who overdosed (p=0.001).
Multivariable Analysis
In the multivariable multinomial model, drug-related stigma score was positively associated 
with overdose (Table 2). Each one-unit increase in stigma z-score was associated with 70% 
higher odds of experiencing an overdose in the past year (95% Confidence Interval [CI]: 
1.1–2.7) and 50% higher odds of experiencing an overdose over a year ago (95% CI: 1.1–
2.0) after adjustment for age, race, gender, education, homelessness, number of drug use 
settings, opioid use, receiving addiction treatment, syringe exchange use, and selling drugs. 
In subanalyses that separately examined the association of stigma subtypes, enacted stigma 
score was positively associated with overdosing in the past year (adjusted Odds Ratio [aOR]: 
2.0, 95% CI: 1.3–3.2) and >1 year ago (aOR: 1.6, 95% CI: 1.2–2.1, Supplemental Table 2). 
However, internalized stigma score was not associated with overdosing in the past year 
(aOR: 1.2, 95% CI: 0.8–1.8) and was marginally associated with overdosing >1 year ago 
(aOR: 1.3, 95% CI: 1.0–1.7, p=0.07).
The total number of drug use settings reported by a participant was also positively associated 
with experiencing an overdose both in the last year and over a year ago. For each additional 
drug use setting reported by a participant, the odds of overdosing was 30% higher regardless 
of the timing of the last overdose. In subanalyses that examined the type of space, each 
additional public setting was associated with a 40% higher odds of overdosing (regardless of 
the timing of the last overdose) whereas the number of private spaces was not associated 
with overdose (Supplemental Table 2). Injecting heroin or speedball was associated with 
approximately a 4-fold higher odds of experiencing an overdose. Snorting heroin, misusing 
prescription opioids, syringe exchange use, and selling drugs were not significantly 
associated with overdose in the adjusted multinomial regression model. A sensitivity 
analysis suggested that the associations of overdose with stigma and drug use settings were 
driven by occurrence rather than frequency of overdose (Supplemental Table 3).
DISCUSSION
We found that experiencing discrimination from others or stereotyping (i.e., enacted stigma) 
related to using drugs and using drugs in public settings were associated with recent and 
lifetime overdose history. These findings highlight the need to identify the mechanisms by 
which enacted stigma increases overdose risk so that overdose prevention strategies in 
Baltimore City and beyond can address the excess risk of overdose among stigmatized 
individuals. In addition, our finding of an association of overdose with injection at multiple 
venues suggests that PWUD should be recruited from multiple types of public settings for 
overdose education and response training and naloxone distribution.
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Our findings around enacted stigma agreed with a study by Couto e Cruz et al. (2018), who 
found a 60% higher odds of experiencing an overdose among Australians who experienced 
persistent discrimination for injecting drugs. Surprisingly, internalized stigma was only 
marginally associated with overdose in our study, and the relationship was weaker in 
magnitude than that for enacted overdose. The differing associations of overdose with 
internalized and enacted stigma suggest that overlapping mechanisms by which both types 
of stigma increase overdose risk, such as through their positive associations with depression, 
do not fully explain the relationship of enacted stigma with overdose (Cama et al., 2016; 
Couto E Cruz, Salom, Maravilla, & Alati, 2018; Kulesza et al., 2013; von Hippel et al., 
2018). One plausible mechanism by which enacted stigma could increase overdose risk is by 
encouraging dangerous injection behaviors, such as rushing drug use, to avoid being 
observed by bystanders. While there is limited prior work to inform this hypothesis, studies 
on police presence, which has been cited as a reason for rushed injecting, may be relevant, as 
a motivation for avoiding arrest by police is to avoid being identified as a person using drugs 
by bystanders (Cooper, Moore, Gruskin, & Krieger, 2005; Ti et al., 2015). In addition, 
Wilson et al. found an association between perceived discrimination with being injected by 
someone else, another injection risk behavior that could lead to an overdose (Wilson et al., 
2014). Hesitancy to attend overdose prevention trainings or carry naloxone, using alone, 
hiding drug use, and discrimination from addiction treatment or other healthcare providers 
could also contribute to the increased risk of overdose that is associated with enacted stigma. 
It is also possible that greater addiction severity may lead to more drug buying, selling, 
consumption, and other consequences of drug use (e.g., incarceration) that increase stigma 
and overdose risk concurrently (Couto E Cruz, Salom, Maravilla, et al., 2018; Kulesza et al., 
2013).
Further research on the longitudinal and contextual relationships between enacted and 
internalized stigma and overdose may aid in developing overdose prevention interventions. 
These two dimensions of stigma may have different roles, with interventions for PWUD 
having a greater focus on internalized stigma and interventions for health care providers, 
family members, and community settings focusing on enacted stigma. Social marketing 
campaigns have successfully been used to reduce HIV stigma, and such approaches could 
also be utilized to address stigma towards PWUD (Blankenship, Bray, & Merson, 2000; 
Mahajan et al., 2008; Rimal & Creel, 2008). Online trainings may be effective to reduce 
negative and discriminatory attitudes among healthcare workers against PWUD (Brener, 
Cama, Hull, & Treloar, 2017).
The finding that a greater number of public drug use settings are associated with overdose 
suggests that expanding overdose prevention and naloxone training into public settings 
frequented by PWUD may help reach populations who do not access training through 
syringe exchange services. While just over a quarter of participants reported using the 
syringe exchange program in the past six months, half reported using outside, and many 
reported using in other locations as described above. These results highlight the potential for 
diversification of settings for naloxone training and distribution as well as the potential to 
involve community members through a peer outreach approach to diffuse overdose 
prevention information in settings of drug consumption that may be difficult to reach by 
health professionals (e.g., shooting galleries and crack houses). Further, these results 
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complement previous findings that supported expanding settings for overdose interventions 
based on the presence of overdose witnesses (Latkin, Edwards, Davey-Rothwell, Yang, & 
Tobin, 2018).
While harm reduction programs have trained people who use opioids to successfully 
administer naloxone, there remains a pressing need to train PWUD to educate their peers to 
diffuse overdose prevention and treatment training skills and encourage PWUD to carry 
naloxone (Sherman et al., 2009). Working with PWUD to identify contextual characteristics 
of drug use settings that influence overdose prevention and response may also be valuable to 
inform strategies for peer-driven intervention. For example, what are the range of norms and 
policies across different types of settings related to naloxone availability, expectations about 
peer monitoring, and overdose response procedures and what factors help to produce 
contexts that better facilitate safety? Whereas public bathrooms present challenges around 
identifying an overdose due to using alone (Fairbairn, Coffin, & Walley, 2017; Holloway, 
Hills, & May, 2018), shooting galleries have the opposite characteristic: an association with 
larger social networks and sharing injecting equipment (Tobin, Davey-Rothwell, & Latkin, 
2010). The social relationships of PWUD in public settings, or lack thereof, may also guide 
expectations for responding to a witnessed overdose, calling for medical assistance, or 
monitoring overdose victims (Holloway et al., 2018). Future research should examine the 
mechanisms by which different drug use settings contribute to overdose so that the risks may 
be adequately addressed.
The association between syringe exchange utilization and experiencing an overdose was 
attenuated after adjusting for heroin and cocaine injection (i.e., speedball). This change is 
not surprising because the vast majority of individuals who attend syringe exchange 
programs inject drugs. Nonetheless, the fact that >40% of participants who overdosed 
attended the syringe exchange provides strong support for continued outreach to people who 
inject drugs at syringe exchanges for overdose education and naloxone distribution. As 
overdose from heroin and synthetic opioids continues to present a major risk to people who 
inject drugs, the BCNEP’s existing overdose prevention and naloxone program will be a 
critical resource in preventing overdose deaths.
This study has several limitations. The study’s findings are limited in generalizability to 
individuals meeting the parent clinical trial’s eligibility criteria (presence of HIV risk 
behaviors, aged 18–55, and willing to attend study visits). Additionally, we relied on self-
reported data for overdose history. Overdose was described to participants as “a life-
threatening condition that occurs after someone has taken drugs by injection or by any other 
route.” This leaves room for personal interpretation by the participant, and there is no way of 
determining whether overdose experiences were under- or over-reported. However, unlike 
medical records or hospital admissions, self-reported overdose data captures overdoses that 
are unreported (Darke, Mattick, & Degenhardt, 2003). Furthermore, it is unknown what 
percentage of reported overdoses were caused by drugs other than opioids and therefore 
would not respond to naloxone administration. However, 94% of study participants had a 
history of opioid use. Thus it is likely that most reported overdoses were caused by opioids 
or opioids in combination with other drugs. In addition, these data were cross-sectional and 
cannot establish the temporal sequence between stigma, drug use, and overdose. It is 
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plausible that having an overdose, in and of itself, could increase stigma, and that this could 
in turn increase the risk of future overdose. Longitudinal studies to further characterize these 
relationships are warranted. We also did not have reports on where participants had injected 
more than 6 months ago. Participants in our study either never exchanged or exchanged 
syringes infrequently (less than once per month). We were therefore unable to examine the 
relationship of overdose and frequency of exchanging syringes or accessing other harm 
reduction services at the syringe exchange program. These data also do not capture the 
experiences of users who have succumbed to fatal overdose and therefore could not 
participate in the study. It is plausible that unique risk factors exist for fatal overdose and 
these should be addressed in future research.
It should also be noted that this study was conducted before the influx of synthetic opioids 
(i.e., fentanyl and fentanyl analogs) on the drug market and preceded recent local policies 
that increased the availability of naloxone. In October 2015, the Baltimore City Health 
Commissioner issued a standing order for naloxone (i.e., a blanket prescription covering 
anyone in the city who presents a certificate from a state-approved naloxone training 
program) (Baltimore City Health Department, 2015). Since then, more than 20,000 
Baltimore residents have been trained through the Baltimore City Health Department, with 
>800 reported overdose reversals (Baltimore City Health Department, 2017a). In June 2017, 
an additional standing order removed the training requirement, making naloxone accessible 
to all residents (Baltimore City Health Department, 2017b). The impact of standing orders 
on stigma and overdose prevalence and mortality has not yet been determined. It is unlikely 
that changes in rates of overdose or standing orders have dramatically changed the level of 
stigma experienced by PWUD.
Our results suggest the potential utility of supplementing existing overdose education and 
naloxone distribution policies in Baltimore with measures that reduce stigma. For example, 
peer educator programs that connect PWUD who are disengaged with harm reduction 
services to peers engaged with harm reduction services could help minimize the impact of 
stigma associated with drug use, which may facilitate carrying naloxone, attending overdose 
trainings, or accessing syringe services programs. Moreover, providing PWUD with 
prosocial options for engaging in harm reduction in the community, such as becoming peer 
educators, may help to reduce self-stigma. Further, additional training to destigmatize drug 
use is warranted for health professionals, social service providers, families of PWUD, and 
the general public.
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Table 2.
Adjusted associations of overdose experiences with stigma, drug use settings, and drug use history among 
people who use drugs in Baltimore, MD – 2009–2012 (n=444)
Covariate
Timing of Most Recent Overdose
(Ref: Never Overdosed)
≤1 Year Ago >1 Year ago
OR(95% CI) aOR (95% CI) OR (95% CI) aOR (95% CI)
Stigmaa 2.0 (1.4–2.9)* 1.7 (1.1–2.7)* 1.5 (1.2–1.9)* 1.5 (1.1–2.0)*
Total Number of Drug Use Settingsb 1.5 (1.2–1.8)* 1.3 (1.0–1.7)* 1.3 (1.2–1.5)* 1.3 (1.1–1.6)*
Injected Heroin and/or Speedball 3.9 (2.3–6.6)* 4.3 (2.2–8.3)* 3.6 (2.7–4.8)* 3.9 (2.7–5.7)*
Snorted Heroin 0.9 (0.6–1.5) 0.9 (0.5–16) 0.7 (0.6–1.0)* 0.8 (0.5–11)
Misused Prescription Opioids 1.8 (1.2–2.6)* 1.3 (0.9–2.1) 1.3 (1.1–1.7)* 1.1 (0.8–14)
Any Addiction Treatment 1.6 (0.9–2.7) 1.4 (0.7–2.5) 1.5 (1.1–2.0)* 1.3 (0.9–19)
Exchanged Syringes through the BCNEPb 3.7 (1.8–8.1)* 0.7 (0.3–1.9) 3.3 (2.1–5.2)* 0.6 (0.3–1.2)
Sold Drugsc 2.7 (1.1–6.6)* 1.8 (0.6–5.1) 1.8 (1.0–3.3) 1.3 (0.6–2.7)
Age <45 Years 1.3 (0.6–2.7) 0.5 (0.2–1.2) 0.9 (0.6–1.3) 0.4 (0.2–0.8)*
Male Gender 0.7 (0.4–1.5) 0.5 (0.2–11) 1.1 (0.7–1.6) 0.7 (0.4–1.2)
African American 0.3 (0.1–0.7)* 1.1 (0.4–3.3) 0.4 (0.2–0.7)* 1.1 (0.5–2.4)
Education ≤11th Grade 0.6 (0.3–1.3) 0.5 (0.2–1.1) 1.0 (0.6–1.5) 0.8 (0.5–1.4)
Homelessnessb 1.7 (0.8–3.5) 1.1 (0.4–2.7) 0.9 (0.6–1.4) 0.6 (0.4–11)
Incarceratedb 0.9 (0.4–2.1) -- 1.3 (0.8–2.0) --
Unemployedb 2.2 (0.3–16.7) -- 1.4 (0.5–3.6) --
a
Z-Score
b
In the past 6 months.
c
In the past 30 days.
*p<0.05.
Abbreviations: aOR: Adjusted Odds Ratio; BCNEP: Baltimore City Needle Exchange Program; OR: Bivariate Odds Ratio; Ref: referent category; 
95% CI: 95% Confidence Interval
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